Percutaneous Coronary Intervention clinical trials at University of California Health
3 in progress, 1 open to eligible people
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
open to eligible people ages 18 years and up
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
at UCLA
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
Sorry, in progress, not accepting new patients
To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.
at UCLA UCSD
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Sorry, not yet accepting patients
The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).
at UC Davis
Our lead scientists for Percutaneous Coronary Intervention research studies include Garrett Wong, M.D. Quang Bui, MD.
Last updated: